(Q37263338)

19 August 2017

1 reference

title

Hypoxia, angiogenesis, and lung cancer (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

Ranjit K Goudar

1

1 reference

PubMed ID

18778551

19 August 2017

Gordana Vlahovic

series ordinal

2

1 reference

19 August 2017

1 July 2008

1 reference

19 August 2017

Current Oncology Reports

1 reference

19 August 2017

10

1 reference

19 August 2017

4

1 reference

19 August 2017

277-282

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-008-0043-6

19 August 2017

0 references

cites work

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

1 reference

12 December 2020

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

1 reference

12 December 2020

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

12 December 2020

New antiangiogenetic agents and non-small cell lung cancer

1 reference

12 December 2020

Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma

1 reference

12 December 2020

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

12 December 2020

Cyclooxygenase as a target in lung cancer

1 reference

12 December 2020

Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment

1 reference

12 December 2020

The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

1 reference

12 December 2020

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

12 December 2020

The potential role of intrinsic hypoxia markers as prognostic variables in cancer

1 reference

12 December 2020

Osteopontin Expression and Prognostic Significance in Non-Small Cell Lung Cancer

1 reference

12 December 2020

Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer

1 reference

12 December 2020

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 reference

12 December 2020

Bevacizumab in the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer

1 reference

12 December 2020

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer.

1 reference

12 December 2020

The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer

1 reference

12 December 2020

A Randomized Phase II Study of Sorafenib/Gemcitabine or Sorafenib/Erlotinib for Advanced Non–Small-Cell Lung Cancer in Elderly Patients or Patients with a Performance Status of 2: Treatment Rationale and Protocol Dynamics

1 reference

12 December 2020

PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis

1 reference

12 December 2020

Plasma osteopontin is an independent prognostic marker for head and neck cancers

1 reference

12 December 2020

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

1 reference

12 December 2020

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas

1 reference

12 December 2020

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments

1 reference

12 December 2020

Inhibition of angiogenesis in the treatment of non-small cell lung cancer

1 reference

12 December 2020

Angiogenesis inhibitors in the treatment of lung cancer

1 reference

12 December 2020

Angiogenesis and lung cancer: prognostic and therapeutic implications

1 reference

12 December 2020

The histological structure of some human lung cancers and the possible implications for radiotherapy

1 reference

12 December 2020

Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes

1 reference

12 December 2020

Role of osteopontin in tumour progression

1 reference

12 December 2020

Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

12 December 2020

The potential of antiangiogenic therapy in non-small cell lung cancer.

1 reference

12 December 2020

10.1007/S11912-008-0043-6

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18778551